About Cabling Installation & Maintenance

Our mission: Bringing practical business and technical intelligence to today's structured cabling professionals

For more than 30 years, Cabling Installation & Maintenance has provided useful, practical information to professionals responsible for the specification, design, installation and management of structured cabling systems serving enterprise, data center and other environments. These professionals are challenged to stay informed of constantly evolving standards, system-design and installation approaches, product and system capabilities, technologies, as well as applications that rely on high-performance structured cabling systems. Our editors synthesize these complex issues into multiple information products. This portfolio of information products provides concrete detail that improves the efficiency of day-to-day operations, and equips cabling professionals with the perspective that enables strategic planning for networks’ optimum long-term performance.

Throughout our annual magazine, weekly email newsletters and 24/7/365 website, Cabling Installation & Maintenance digs into the essential topics our audience focuses on.

  • Design, Installation and Testing: We explain the bottom-up design of cabling systems, from case histories of actual projects to solutions for specific problems or aspects of the design process. We also look at specific installations using a case-history approach to highlight challenging problems, solutions and unique features. Additionally, we examine evolving test-and-measurement technologies and techniques designed to address the standards-governed and practical-use performance requirements of cabling systems.
  • Technology: We evaluate product innovations and technology trends as they impact a particular product class through interviews with manufacturers, installers and users, as well as contributed articles from subject-matter experts.
  • Data Center: Cabling Installation & Maintenance takes an in-depth look at design and installation workmanship issues as well as the unique technology being deployed specifically for data centers.
  • Physical Security: Focusing on the areas in which security and IT—and the infrastructure for both—interlock and overlap, we pay specific attention to Internet Protocol’s influence over the development of security applications.
  • Standards: Tracking the activities of North American and international standards-making organizations, we provide updates on specifications that are in-progress, looking forward to how they will affect cabling-system design and installation. We also produce articles explaining the practical aspects of designing and installing cabling systems in accordance with the specifications of established standards.

Cabling Installation & Maintenance is published by Endeavor Business Media, a division of EndeavorB2B.

Contact Cabling Installation & Maintenance

Editorial

Patrick McLaughlin

Serena Aburahma

Advertising and Sponsorship Sales

Peter Fretty - Vice President, Market Leader

Tim Carli - Business Development Manager

Brayden Hudspeth - Sales Development Representative

Subscriptions and Memberships

Subscribe to our newsletters and manage your subscriptions

Feedback/Problems

Send a message to our general in-box

 

Charles River Laboratories’ Industry Experts to Present Advanced Modalities at Neuroscience 2023

Charles River Laboratories International, Inc. (NYSE: CRL) today announced that its team of neuroscience drug discovery experts will present 19 scientific posters, both independently and collaboratively with clients, at Neuroscience 2023, the annual meeting of the Society for Neuroscience (SfN). The meeting, which brings together leading researchers from across the globe, will take place from November 11-15 in Washington, DC.

“Neuroscience is one of the most complex areas of drug discovery,” Antti Nurmi, PhD, MSc, Regional General Manager, Europe, Charles River. “I am excited about recent advances in this field, especially innovations in how we are using artificial intelligence and machine learning. These innovations will ultimately accelerate success in this critical field of drug development.”

Highlighting Scientific Leadership

Throughout the conference, Charles River experts will present posters and host discussions on the latest developments in neuroscience research and innovative approaches to tackling neurodegenerative disorders. Posters are being presented on a range of topics, including phenotypic screening and cell models, the utilization of artificial intelligence (AI) and machine learning (ML) in preclinical imaging, and research into Huntington’s disease.

  • Dose-dependent Modulation of brain activity by Psilocybin in mice: Insights from Functional Ultrasound Imaging (Presented by Susanne Back: Sunday, November 12, 9:00-10:00 AM EST)
  • Improved Kinematic Gait Phenotype in hDMDdel52/mdx mouse model of Duchenne Muscular Dystrophy after Treatment with Antisense Oligonucleotide BMN351 (Presented by Jussi Rytkonen: Sunday, November 12, 1:00-2:00 PM EST)
  • Development of an ASO-based therapy targeting UBE3A for a patient with Dup15q Syndrome (Presented by Malika Bsibsi: Monday, November 13, 1:00-2:00 PM EST)
  • Characterization of conditional Q175 (cQ175) and Q20 (cQ20) knockout models (Presented by Susanne Back: Wednesday, November 15, 3:00-4:00 PM EST)

“For patients suffering with neurodegenerative disease, innovation in this field is critical,” said Gunnar Flik, Site Director, Groningen at Charles River. “At Charles River, we have over 20 years of experience, and a team of industry-leading experts who are dedicated to advancing the pace of research.”

Partnerships Driving Innovation in Neuroscience

On Monday, November 13, from 6:30-9:00 PM EST at the Westin Washington DC Downtown (Anacostia Ballroom), the Charles River team will host a networking reception where thought leaders will be available to discuss topics including selecting appropriate models and assays, translation of preclinical studies into clinical success, and how the right partner can support programs from drug discovery through regulatory approval to commercialization.

On Tuesday, November 14, at 4:00 PM EST, Dr. Malika Bsibsi, Research Leader at Charles River will participate in a showcase with Dr. Javier Conde-Vancells, Director Product Management, bit.bio, to share data on the functional and consistency properties of human induced pluripotent stem cell (hiPSC)-derived ioMicroglia™. bit.bio and Charles River have a long-standing strategic partnership focused on the development and characterization of wild type and disease state hiPSC-derived neurons and muscle cells. For years, widely used protocols for generating hiPSC-derived microglia have required long, complex workflows that suffer from lot-to-lot inconsistency. This presentation will highlight the use of hiPSC-derived ioMicroglia™ in assays, including phagocytosis, cytokine secretion and chemotaxis, in just 10 days post-thaw.

Lastly, the increased use of AI/ML in drug discovery has allowed medicinal chemists to operate at a vastly different scale than traditional approaches, by enabling them to search much larger universes of potential compounds. In 2022, Charles River and Valo Health launched Logica™, an AI-powered solution that directly translates clients’ biological insights into optimized preclinical assets. Members of the Logica team will be available to discuss the unique risk-sharing model of Logica that ties costs to value generation points

A full schedule of Charles River’s activities during Neuroscience 2023 is available online. Additionally, experts will be available at Booth #1717 for meetings with those interested in discussing neuroscience research and drug discovery.

About Charles River

Charles River provides essential products and services to help pharmaceutical and biotechnology companies, government agencies and leading academic institutions around the globe accelerate their research and drug development efforts. Our dedicated employees are focused on providing clients with exactly what they need to improve and expedite the discovery, early-stage development and safe manufacture of new therapies for the patients who need them. To learn more about our unique portfolio and breadth of services, visit www.criver.com.

Contacts

Investor Contact:

Todd Spencer

Corporate Vice President, Investor Relations

781-222-6455

todd.spencer@crl.com

Media Contact:

Amy Cianciaruso

Corporate Vice President, Public Relations

781-222-6168

amy.cianciaruso@crl.com

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.